Letrozol Tecnimede

Letrozole, the active ingredient in Letrozol Tecnimede, is an aromatase inhibitor presented as a tablet for oral use. It is employed to treat hormone receptor‑positive breast cancer in postmenopausal women, both in early‑stage adjuvant settings and in metastatic disease. The medication works by reducing estrogen production, thereby limiting tumor growth.

GNH USA supplies Letrozol Tecnimede as a licensed, GDP‑compliant international pharmaceutical supplier serving oncology centres, hospitals and pharmacies worldwide, ensuring quality and regulatory conformity for global distribution and reliable delivery services.

Letrozole is used in the management of hormone‑dependent breast cancer, targeting estrogen‑driven tumor growth.

Early‑stage hormone receptor‑positive breast cancer: reduces risk of recurrence when given as adjuvant therapy. Metastatic hormone receptor‑positive breast cancer: delays disease progression and improves survival. Extended adjuvant therapy after tamoxifen: provides continued estrogen suppression to prevent late recurrence.

Letrozole may cause a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Hot flashes: transient warmth and sweating. - Joint and muscle pain: arthralgia and myalgia. - Fatigue: persistent tiredness. - Nausea: mild to moderate upset stomach.

Serious or Rare Side Effects: - Severe liver injury: jaundice or elevated enzymes. - Bone fracture or osteoporosis: increased risk of skeletal fragility. - Pulmonary embolism or deep vein thrombosis: signs of clot formation in lungs or veins.

Before initiating Letrozole therapy, several safety considerations should be reviewed.

Pregnancy: contraindicated (Category X); avoid use in pregnant women. Bone health: assess baseline bone mineral density and consider calcium/vitamin D supplementation. Cardiovascular risk: evaluate history of thromboembolic events before treatment. Liver function: perform hepatic function tests and monitor periodically. Drug interactions: review concomitant medications for potential CYP2C19 inhibitors or estrogen‑containing agents. Store at ambient temperature below 25°C: keep in original packaging, protect from moisture and light.

Letrozole can interact with other medicines, affecting its efficacy or safety.

Major Interactions (Avoid): - Strong CYP2C19 inhibitors (e.g., fluconazole, voriconazole): may increase letrozole plasma concentrations. - Estrogen‑containing products (hormone replacement therapy, oral contraceptives): antagonize therapeutic effect.

Moderate Interactions (Monitor Closely): - Anticoagulants (warfarin): may require INR monitoring due to altered metabolism. - Tamoxifen: concurrent use can reduce effectiveness of both agents. - Selective serotonin reuptake inhibitors (e.g., fluoxetine): may modestly affect letrozole clearance.